Table 9.

Adverse effects reported by clinical investigators

Observed adverse events	Treatment group						P‐valueb
	Torasemide			Furosemide
	n = 180	Study 1 n = 75	Study 2 n = 105	n = 186	Study 1 n = 76	Study 2 n = 110
“Overpharmacology” (polyuria‐polydipsia and/or urinary “incontinence” (as reported by the owners) related to a potent diuretic effect), n (%)	36 (20)	9 (12)	27 (26)	8 (4)	2 (3)	6 (5)	<0.001
Gastrointestinal disorders (e.g, vomiting, diarrhea, anorexia), n (%)	31 (17)	10 (13)	21 (20)	21 (11)	6 (8)	15 (14)	0.10
Respiratory, n (%)	2 (1)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0.24
Neoplasia n (%)	3 (2)	1 (1)	2 (2)	0 (0)	0 (0)	0 (0)	0.12
Hepatic enzyme elevation, n (%)	5 (3)	2 (3)	3 (3)	0 (0)	0 (0)	0 (0)	0.028
Electrolyte disorders, n (%)	6 (3)	5 (7)	1 (1)	8 (4)	8 (11)	0 (0)	0.63
Urinary, n (%)	4 (2)	1 (1)	3 (3)	0 (0)	0 (0)	0 (0)	0.058
Neurological, n (%)	4 (2)	1 (1)	3 (3)	10 (5)	4 (5)	6 (5)	0.12
Ocular, n (%)	2 (1)	0 (0)	2 (2)	5 (3)	3 (4)	2 (2)	0.45
Dermatological (dermatitis, otitis externa), n (%)	5 (3)	2 (3)	3 (3)	4 (2)	2 (3)	2 (2)	0.75
Reproduction, n (%)	5 (3)	1 (1)	4 (4)	1 (1)	0 (0)	1 (1)	0.12
Renala, n (%)	32 (18)	17 (23)	15 (14)	8 (4)	2 (3)	6 (5)	<0.001
Integumentary (e.g, bite wounds, lacerations, declaw), n (%)	3 (2)	0 (0)	3 (3)	3 (2)	3 (4)	0 (0)	1.00
Muscular disorders (muscle tremors, lameness), n (%)	3 (2)	1 (1)	2 (2)	5 (3)	2 (3)	3 (3)	0.72
Others, n (%)	13 (7)	4 (5)	9 (9)	15 (8)	4 (5)	11 (10)	0.76

^aRenal as per VeDDRA preferred term. In other words, renal effects covered all renal events from the most severe (acute renal failure) to the least severe (elevated renal parameters when compared to baseline, even if still within the reference ranges and even if not associated with clinical signs).

^bTorasemide group (n = 180) versus Furosemide group (n = 186).

P‐values that appear in bold are < 0.05.